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Abstract
Introduction: Dilated cardiomyopathy (DCM) is associated with significant morbidity and mortality. Contrast-enhanced cardiac MRI 
(CE-CMR) can detect potentially prognostic myocardial fibrosis in DCM. We investigated the role of CE-CMR in New Zealand patients 
with DCM, both Maori and non-Maori, including the characteristics and prognostic importance of fibrosis.
Methods: One hundred and three patients (mean age 58 ± 13, 78 male) referred for CMR assessment of DCM were followed for 
660 ± 346 days. Major adverse cardiac events (MACE) were defined as death, infarction, ventricular arrhythmias or rehospitalisation. 
CE-CMR used cines for functional analysis, and delayed enhancement to assess fibrosis.
Results: Myocardial fibrosis was present in 30% of patients, the majority of which was mid-myocardial (63%). Volumetric parameters 
were similar in patients with or without fibrosis. At 2 years patients with fibrosis had an increased rate of MACE (HR = 0.77, 95% 
CI 0.3–2.0). Patients with full thickness or subendocardial fibrosis had the highest MACE, even in the absence of CAD). More Maori 
had fibrosis on CE-CMR (40% vs. 28% for non-Maori), and the majority (75%) was mid-myocardial. Maori and non-Maori had similar 
outcomes (25% vs. 24% with events during follow-up).
Conclusions: DCM patients frequently have myocardial fibrosis detected on CE-CMR, the majority of which is mid-myocardial. 
  Fibrosis is associated with worse outcome in the medium term. The information obtained using CE-CMR in DCM may be of   incremental 
clinical benefit.
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Introduction
Dilated  non-ischaemic  cardiomyopathy  (DCM)  is 
associated with significant morbidity and mortality.1 
Contrast-enhanced cardiac magnetic resonance imag-
ing (CE-CMR) can detect myocardial scar in vivo with 
high  sensitivity,  specificity  and  spatial  resolution,2 
and has the potential to provide diagnostic and prog-
nostic information in this group of patients. Initial 
reports using CE-CMR suggest that approximately 
one third of patients with DCM may have myocar-
dial  scar,  as  detected by  late gadolinium enhance-
ment (LGE).3 It has been suggested that the presence 
of LGE has incremental prognostic implications,4 and 
may identify those with DCM at risk of progressive 
deterioration. We further evaluated this hypothesis in 
New Zealand patients, including an important cohort 
of Maori, investigating the frequency and characteris-
tics of LGE, and assessing its prognostic importance 
in medium-term follow-up.
Methods
Patients
Patients  with  DCM  (n  =  103)  were  prospectively 
identified between December 1st 2003 and August 
31st 2006. Patients were included in the analysis if 
they had: (a) a clinical presentation of heart failure (b) 
an echocardiogram demonstrating impaired left ven-
tricular  systolic  function  (ejection  fraction  ,50%) 
(c)  successfully  completed  a  CE-CMR.  Patients 
were excluded if: (a) they had significant coronary 
artery disease (.50% diameter luminal stenosis in 
any coronary artery) documented on angiography (b) 
significant  valvular  disease  (c)  cardiomyopathy  of 
known cause including hypertrophic, alcohol- or che-
motherapy induced or infiltrative myopathies. Patient 
events were determined from record review, and all 
patients continued to undergo follow-up at our insti-
tution. The institutional Ethics Committee approved 
this analysis.
Major  adverse  cardiac  events  (MACE)  were 
defined as death, cardiac transplant, sustained ven-
tricular  arrhythmias,  or  rehospitalisation  for  heart 
failure.
Cardiac MrI
CE-CMR was performed on a Philips Intera 1.5Tesla 
magnet using a Synergy Cardiac Coil (Philips, Best). 
Electrocardiographically  gated  steady  state  free 
  precession cine images were acquired in the 2 and 4 
chamber, left ventricular outflow tract and short axis 
views. The sequence parameters were: flip angle 65°, 
TE = 1.64 ms, TR = 3.3 ms, slice thickness 8 mm. 
Delayed enhancement imaging was performed after 
injection of 0.15 mmol/kg gadolinium-based contrast 
agent (Omniscan, Nycomed Amersham, Oslo). A three 
dimensional inversion-recovery segmented gradient 
echo sequence was used in 2 and 4 chamber, left ven-
tricular outflow tract and short axis views. Imaging was 
commenced 10 minutes after contrast administration 
using an inversion time optimised to obtain adequate 
nulling of normal myocardium (260–340 ms). The 
imaging sequence parameters  included an  in-plane 
voxel  size  1.2–1.8  ×  1.2–1.8  mm2,  slice  thickness 
6 mm, flip angle 15, TE = 3–4 ms, and TR = 8–9 ms. 
A Philips EzyVision workstation was used for image 
analysis. LV end-diastolic volume, LV end-systolic 
volume, LV ejection fraction were calculated from 
the short axis cine images. Areas of LGE were defined 
as subendocardial, mid-myocardial or transmural on 
visual analysis by a consensus of two independent 
cardiologists.
Statistics
Data are expressed as a mean ± standard deviation 
(SD). The baseline characteristics of the groups were 
compared with the independent sample t-test for con-
tinuous variables, and Chi-square or Fisher Exact tests 
for categorical variables. Survival estimates and event 
rates were compared by the Kaplan-Meier method. 
The log-rank test was used to compare the Kaplan-
Meier survival curves. The duration of follow-up was 
the day of the CE-CMR scan to August 31st, 2006. 
A P value of ,0.05 was considered significant.
Results
The clinical characteristics of the entire cohort are sum-
marized in Table 1. The mean age was 58 + 13 years, 
with  the  majority  being  male  and  NYHA  Class  I. 
Twenty patients (19%) were New Zealand Maori. The 
latter were predominantly younger men (mean age 
48 ± 16 vs. 61 ± 11, P , 0.05), and had significantly 
higher rates of diabetes and smoking (Table 2).
The  CE-CMR  results  are  presented  in Tables 3 
and  4.  Myocardial  LGE  was  present  in  31  (30%) 
patients, and was mid-myocardial in 21 patients (20%), 
transmural  in  7  patients  (7%)  and    subendocardial CMr in dilated cardiomyopathy
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Table 1. Baseline characteristics: entire cohort.
All patients LGe present
no Yes
no. of patients 103 72 (70%) 31 (30%)
Age (years) 58 ± 13 59 ± 13 57 ± 12
Male/Female 78/25 51/21 27/4
risk factors
• hypertension 36 25 (35%) 11 (35%)
• Dyslipidaemia 31 22 (31%) 9 (29%)
•   Diabetes  
mellitus
19 12 (17%) 7 (23%)
•   Smoker  
(current/ex)
38 22 (31%) 16 (52%)
nYhA class (%)
• I 77 (75%)
• II 18 (18%)
• III 4 (4%)
• IV 0 (0%)
note: Values are means ± SD, or numbers of patients (percentages). 
P = ns for all.
Table 2. Baseline characteristics: Maori vs. non-Maori.
Maori non-Maori
no. of patients 20 (19%) 83 (81%)
Age (years) 48 ± 16* 61 ± 11
Male 96%* 71%
risk factors
• hypertension 7 (35%) 29 (35%)
• Dyslipidaemia 5 (25%) 26 (31%)
• Diabetes mellitus 7 (35%)* 12(14%)
• Smoker (current/ex) 12 (60%)* 26 (31%)
nYhA class (%)
• I 14 (70%) 63 (76%)
• II 4 (20%) 14 (17%)
• III 2 (10%) 2 (2%)
• IV 0 0
note: Values are means ± SD, or numbers of patients (percentages). 
*P , 0.05.
Table 4. Ce-CMr results and MACe: Maori vs.   non-Maori.
ce-cMR results and MAce Maori non-Maori
LV volumes
• LVeDV (mL) 315 ± 88* 260 ± 73
• LVeSV (mL) 235 ± 87* 180 ± 76
• LVSV (mL) 79 ± 27 83 ± 24
• LVeF (%) 26 ± 13* 32 ± 12
Lge location
• Absent 12 (60%) 60 (73%)
• Mid-myocardial 6 (30%) 13 (16%)
• Subendocardial 1 (5%) 4 (5%)
• Transmural 1 (5%) 6 (6%)
MACe 5 (25%) 18 (22%)
• Death 2 (10%) 7 (9%)
• heart failure 2 (10%) 2 (2%)
• Ventricular arrhythmia 1 (5%) 6 (6%)
• Transplant 0 1 (1%)
notes: Values are means ± SD, or numbers of patients (percentages). 
*P , 0.05.
Abbreviations:  LVeDV,  left  ventricular  end  diastolic  volume;  LVeSV, 
left ventricular end systolic volume; LVSV, left ventricular stroke volume; 
LVeF, left ventricular ejection fraction. 
Table 3. Ce-CMr results and MACe: entire cohort.
ce-cMR results  
and MAce
All patients LGe present?
no Yes
LV volumes
• LVeDV (mL) 271 ± 79 265 ± 77 285 ± 83
• LVeSV (mL) 190 + 81 184 ± 81 205 ± 80
• LVSV (mL) 82 + 25 82 ± 25 81 ± 24
• LVeF (%) 32 + 12 33 ± 12 29 ± 10
Lge location
• Absent 72 (70%) 72 (100%)
• Mid-myocardial 21 (20%) 21 (68%)
• Subendocardial 3 (3%) 3 (10%)
• Transmural 7 (7%) 7 (23%)
MACe 21 (20%) 10 (10%) 11 (11%)
• Death 9 (9%) 7 (10%) 2 (7%)
• heart failure 4 (4%) 1 (1%) 3 (10%)
•   Ventricular 
arrhythmia
7 (7%) 1 (1%) 6 (19%)
• Transplant 1 (1%) 1 (1%) 0 (0%)
note: Values are means ± SD, or numbers of patients (percentages). 
P =  ns for all.
Abbreviations:  LVeDV,  left  ventricular  end  diastolic  volume;  LVeSV, 
left ventricular end systolic volume; LVSV, left ventricular stroke volume; 
LVeF, eft ventricular ejection fraction.
in 3 patients (3%). Representative images of LGE in 
each category are illustrated in Figure 1. Volumetric 
measurements were similar in those with or without 
LGE. A higher proportion of Maori had LGE (40% 
vs. 28% for non-Maori, P = ns), and the majority was 
mid-myocardial  (75%).  Maori  patients  had  signifi-
cantly larger LV volumes and worse systolic function 
than non-Maori.
The  mean  duration  of  follow-up  was 
660 ± 346 days. There were 9 deaths and LGE was 
present in 2. There was no significant difference in 
all-cause mortality between patients with and without 
LGE (P = 0.58). There was a trend towards a greater 
occurrence  of  MACE  (Hazard  ratio  0.77;  95%CI 
0.29–1.97, P . 0.05) in patients with LGE (Fig. 2). 
Notably there was a higher incidence of ventricular 
arrhythmias in patients with LGE, although this did Looi et al
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not reach statistical significance. The worst outcomes 
were found in patients with transmural LGE, despite 
the proven absence of coronary artery disease in this 
group (Fig. 3). Despite the large ventricular volumes 
and greater incidence of LGE, outcomes were similar 
for both Maori and non-Maori (25% vs. 23% MACE 
during follow-up, P = ns). (Fig. 4)
Discussion
This study demonstrates that CE-CMR imaged LGE 
consistent with myocardial fibrosis is found in nearly 
one third of DCM, and that both the presence and 
  pattern  of  LGE  are  associated  with  medium-term 
prognosis.  The  study  also  highlights  potentially 
important  differences  in  the  morphology  of  DCM 
between Maori and non-Maori patients.
The overall occurrence of LGE (30%) was similar 
to that noted in previous studies of Assomull et al4 
Figure 1. representative Ce-CMr four chamber images of three patients with DCM and no coronary artery disease demonstrating (A) Mid-myocardial, 
(B) Subendocardial and (c) Transmural Lge.
100
95
90
85
80
75
70
0 100 200 300 400
Time (days)
Event
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
 
(
%
)
500 600
Fibrosis
No fibrosis
700
Figure 2. Kaplan-Meier analysis demonstrating event free survival in 
patients with or without myocardial Lge detected by Ce-CMr.
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Figure 3. Kaplan-Meier analysis demonstrating event free survival in 
patients with LGE, stratified by LGE location.
and  McCrohon  et  al,3  but  less  than  reported  by 
Wu et al (42%).5 The pattern of LGE was also simi-
lar to that previously described, with the majority of 
fibrosis being located in the mid-wall but a signifi-
cant minority being transmural (23% of patient with 
LGE). The potential mechanisms for mid-wall fibrosis 
have been considered to include: exposure to patho-
gens and toxins, microvascular ischaemia, abnormal 
immune and metabolic responses such as renin-al-
dosterone system overactivity, and genetic factors.6–10 
In particular CE-CMR imaging in patients with acute 
myocarditis may show mid-wall and epicardial LGE 
that persists in convalescent imaging.11 Subclinical 
myocarditis has been implicated as the aetiology of 
DCM in a significant proportion of patients,12 and the 
similarity in LGE findings on CE-CMR would sup-
port this. The finding of transmural or subendocardial 
fibrosis in the absence of obstructive coronary disease CMr in dilated cardiomyopathy
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has also been described.3,13 It is postulated that this 
may result from thrombosis and subsequent recanali-
sation associated with coronary atheroma, or coro-
nary embolus.
The  finding  of  an  association  between  adverse 
prognosis and the presence of LGE on CE-CMR con-
firms the results of studies by both Assomull et al4 
and Wu et al.5 Our results do not meet a threshold 
of statistical significance, but the reasons for this are 
unclear. Our population may be a lower risk cohort to 
that in both prior studies. The majority of our patients 
were asymptomatic (NYHA Class I 75%, as com-
pared with 15% in Wu et al5 and 23% in Assomull 
et al4), and ventricular function was better (Wu et al: 
ejection fraction 22% in LGE positive patients vs. 
32% in our group). Overall event rates in follow-up 
are lower in our cohort (Assomull et al 26% vs. 21% 
in this study). A lower risk profile for the study popu-
lation may have attenuated the prognostic impact of 
LGE. The higher rate of ventricular arrhythmias in 
our LGE positive patients is consistent with prior data 
from CE-CMR studies, but should also be interpreted 
with caution given the low numbers in this study. Par-
tial thickness LGE on CE-CMR has been shown to 
correlate with inducible VT in patients with DCM,14 
as has infarct tissue heterogeneity.15 An increase in 
scar-related  re-entrant  ventricular  tachyarrhythmias 
in LGE positive patients has also be shown in other 
forms of myocardial disease, including hypertrophic 
cardiomyopathy.16 Our data also raise the possibility 
that the pattern of LGE has an impact on prognosis, a 
finding not previously noted in this context.   However 
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Figure 4. Kaplan Meier analysis demonstrating no significant difference 
in event free survival between Maori and non-Maori.
the small numbers of events limit interpretation of 
this result.
Our study includes the largest reported cohort of 
New Zealand Maori patients with DCM studied by 
CE-CMR. The imaging findings in this group sug-
gest more severe disease, although the prognosis was 
similar  for  Maori  and  non-Maori. The  reasons  for 
the higher prevalence of LGE and worse ventricular 
volumetric results in Maori are not clear. Potentially 
these findings may reflect a more advanced stage of 
disease, suggesting that Maori patients are coming to 
clinical attention later. However if this were the case 
we would have expected to observe a worse outcome 
for Maori—even in the intermediate term. Other pos-
sibilities include an alternative aetiology of DCM in 
Maori,  such  as  a  greater  prevalence  of  subclinical 
myocarditis, or a differing genetic predisposition, but 
this study unfortunately provides no evidence to sup-
port or refute those hypotheses. Further studies should 
be considered in this population.
Limitations
This is a small retrospective study, and suffers from the 
potential biases inherent in such a review. MACE have 
been determined from chart review and may be inac-
curate. Lack of consistently recorded measurements 
of height and weight limits the calculation of indexed 
ventricular volumes on CE-CMR, and makes direct 
comparison between Maori and non-Maori difficult.
conclusions
Patients with DCM frequently have myocardial fibro-
sis detected on CE-CMR, and the occurrence and pat-
tern of this fibrosis is associated with worse outcome in 
the medium term. Maori patients have a higher preva-
lence of fibrosis but similar prognosis to non-Maori. 
The information obtained using CE-CMR may be of 
incremental clinical benefit in patients with DCM.
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